In Europe and Hong Kong
Suven Life Sciences announced the grant of one (1) product patent from Europe (2758394) and one (1) product patent from Hong kong (1173140) corresponding to their New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases.The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.
With these new patents, Suven has a total of sixteen (16) granted patents from Europe and seventeen (17) product patents from Hong Kong.
Powered by Capital Market - Live News
